InterStim® Amplitude Study
Status: | Recruiting |
---|---|
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/3/2019 |
Start Date: | February 27, 2018 |
End Date: | June 1, 2019 |
Contact: | Elizabeth Michaud |
Email: | beth.m.michaud@medtronic.com |
Phone: | 1 (800) 633-8766 |
This feasibility study will explore the effects of three different InterStim amplitude
settings on overactive bladder symptoms (OAB).
settings on overactive bladder symptoms (OAB).
Inclusion Criteria:
1. Primary diagnosis of urinary urge incontinence (UUI) as demonstrated on a 3‐day
baseline voiding diary demonstrating at least 3 UUI episodes
2. Female subjects 18 years of age or older
3. Candidate for InterStim Lead Placement
4. Willing and able to accurately complete voiding diaries, questionnaires, attend
visits, and comply with the study protocol (which includes maintenance of InterStim II
programming settings over the course of the study)
5. Willing and able to provide signed and dated informed consent
6. Willing to maintain current regimen (dosage and frequency) of any overactive bladder
(OAB) medication
Exclusion Criteria:
1. Have neurological conditions such as multiple sclerosis, clinically significant
peripheral neuropathy or spinal cord injury
2. History of diabetes unless the diabetes is well‐controlled through diet and/or
medications
3. Symptomatic urinary tract infection (UTI)
4. Have primary stress incontinence or mixed incontinence where the stress component
overrides the urge component
5. Treatment of urinary symptoms with botulinum toxin in the past 9 months or any plan to
have botulinum toxin treatment during the study
6. Implanted with a neurostimulator, pacemaker, or defibrillator
7. Have knowledge of planned MRIs, diathermy, microwave exposure, high output ultrasonic
exposure, or radio frequency (RF) energy exposure not included within the scanning
conditions provided with the MRI Guidelines for InterStim Therapy
8. Women who are pregnant or planning to become pregnant
9. Characteristics indicating a poor understanding of the study or characteristics that
indicate the subject may have poor compliance with the study protocol requirements.
10. Currently enrolled or planning to enroll in a potentially confounding clinical study
during the course of the study (co-enrollment in concurrent studies is only allowed
when documented pre‐approval is obtained from the Medtronic study manager (or
designee).
We found this trial at
12
sites
300 Grand Avenue
Englewood, New Jersey 07631
Englewood, New Jersey 07631
Phone: 201-510-3178
Click here to add this to my saved trials
11701 San Jose Blvd # 32
Jacksonville, Florida 32223
Jacksonville, Florida 32223
Phone: 904-854-1354
Click here to add this to my saved trials
1211 Medical Center Dr
Nashville, Tennessee 37232
Nashville, Tennessee 37232
(615) 322-5000
Phone: 615-875-2395
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
Click here to add this to my saved trials
Chattanooga, Tennessee 37421
Phone: 423-778-3900
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
West Allis, Wisconsin 53227
Phone: 414-329-5784
Click here to add this to my saved trials
Click here to add this to my saved trials